Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.KRSA · Entity 7698 | Director | September 08, 2026 | September 10, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Financial Officer | January 24, 2018 | January 26, 2018 |
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director | January 09, 2026 | January 13, 2026 |
| PepGen Inc.PEPG · Entity 6253 | Director | June 18, 2026 | June 22, 2026 |
| Perspective Therapeutics, Inc.CATX · Entity 694 | Director | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.06 · Expires 2036-06-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-08 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option vests in 36 equal monthly installments following June 18, 2026, through June 18, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer").
F2: Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option vests in 36 equal monthly installments following June 18, 2026, through June 18, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Kura Oncology, Inc.
Report date January 24, 2018 · Filed January 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2028-01-23 | Direct | 81,000 |
Reported balance
After 2018-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-24 · Grant · Acquired 81,000 · Balance 81,000 F1: This option vests in 48 equal monthly installments commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in 48 equal monthly installments commencing on the grant date.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,725 |
Reported balance
After 2026-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 30,456 · Balance 85,725 F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2: Includes 30,456 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.
F2: Includes 30,456 unvested restricted stock units.
PepGen Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2036-06-17 | Direct | 34,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 34,000 · Balance 34,000 F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 50,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PARDES BIOSCIENCES, INC.
Report date August 31, 2023 · Filed August 31, 2023
Section 16 reporting ended · disclosed 2023-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Other · Disposed 316,753 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2033-01-31 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-31 · Disposition to issuer · Disposed 156,250 · Balance 0 F3: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.88 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-31 · Disposition to issuer · Disposed 241,593 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-31 · Disposition to issuer · Disposed 160,000 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2032-09-13 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-31 · Disposition to issuer · Disposed 125,000 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time).
F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right.
F3: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:05 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000029 · form4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:37 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001283301-26-000008 · ownership.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-03-02 F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:05 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 30,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001283301-26-000003 · wk-form4_1768338320.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,725 F1 · shares: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2 · balance_after: Includes 30,456 unvested restricted stock units. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 10:54 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001127602-25-016931 · form4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:25 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0000950170-25-033649 · ownership.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-03 F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025. F2 · derivative.exercise_date: Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:04 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 15,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001283301-25-000002 · wk-form4_1736802287.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,269 F1 · shares: Represents 15,789 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2026. F2 · balance_after: Includes 15,789 unvested restricted stock units. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 25,975 | $3.85 | $100,003.75 |
DisclosureSEC source: 0000950170-24-134067 · ownership.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Revocable Trust Disclosed balance after: 25,975 Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:11 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001127602-24-019124 · form4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:11 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 23,000 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0000950170-24-076719 · ownership.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:06 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 19,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001283301-24-000002 · wk-form4_1705007207.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,480 F1 · shares: Represents 19,480 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2025. F2 · balance_after: Includes 19,480 unvested restricted stock units. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:30 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001437749-23-034470 · rdgdoc.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930,000 Underlying: Common Stock · 230,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: 100% vests 12/12/2024. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:41 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $2.98 | Not disclosed |
DisclosureSEC source: 0001209191-23-047821 · doc4.xml · derivative · entry 5 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2032-09-13 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:41 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 160,000 | Not disclosed Strike: $11.32 | Not disclosed |
DisclosureSEC source: 0001209191-23-047821 · doc4.xml · derivative · entry 4 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires 2032-01-31 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:41 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 241,593 | Not disclosed Strike: $3.88 | Not disclosed |
DisclosureSEC source: 0001209191-23-047821 · doc4.xml · derivative · entry 3 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241,593 shares Expires 2031-03-17 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:41 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 156,250 | Not disclosed Strike: $2.08 | Not disclosed |
DisclosureSEC source: 0001209191-23-047821 · doc4.xml · derivative · entry 2 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 156,250 shares Expires 2033-01-31 F3 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F3 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F3 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 18:41 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | OtherCommon Stock | 316,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-047821 · doc4.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:11 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001127602-23-019406 · form4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:34 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001437749-23-016757 · rdgdoc.xml · derivative · entry 2 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 230,000 shares Expires 2033-06-02 F2 · derivative.exercise_date: 100% vests 6/2/2024. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:34 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 470,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001437749-23-016757 · rdgdoc.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock · 470,000 shares Expires 2033-06-02 F1 · derivative.exercise_date: Vest monthly over three years. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:29 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 156,250 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006867 · doc4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,250 Underlying: Common Stock · 156,250 shares Expires 2033-02-01 F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 1st day of each month after the Grant Date (02/01/2023), subject to continued service relationship. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:17 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001283301-23-000002 · wf-form4_167347182299908.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents 20,000 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2024. F2 · balance_after: Includes 20,000 unvested restricted stock units. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:12 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001209191-22-050309 · doc4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-09-14 F1 · derivative.exercise_date: Options vest over two years with 1/2 of the shares subject to such option vesting and becoming exercisable on September 14, 2023, and the remaining 1/2 of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 14th day of each month thereafter, subject to continued service relationship. Read SEC document |
| May 06, 2022 Filed May 10, 2022 22:49 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 11,667 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017495 · doc4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 11,667 shares Expires 2032-05-05 F1 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 00:07 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0000899243-22-004219 · doc4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over four years from February 1, 2022, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:27 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 81,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005601 · doc4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 22:28 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-17-005561 · doc4.xml · derivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-22 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| December 13, 2016 Filed Feb 3, 2017 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 2,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007566 · doc5.xml · nonDerivative · entry 2 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 F1 · kind: This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the sale of securities. Read SEC document |
| November 11, 2015 Filed Feb 3, 2017 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007566 · doc5.xml · nonDerivative · entry 1 HENSON HEIDI · CIK 0001283301 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,596 F1 · kind: This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the sale of securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.